期刊
CARDIOVASCULAR RESEARCH
卷 117, 期 13, 页码 2589-2609出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvab330
关键词
Hypertension; Inflammation; Immune system; Immunomodulatory; Blood pressure
资金
- European Research Council [726318]
- British Heart Foundation [PG/19/84/34771, PG/21/10541, RE/13/5/30177]
- Marie Sklodowska Curie CIG Award [3631773]
- Wellcome Trust [204820/Z/16/Z]
- University of Glasgow
- Scottish Funding Council
- Global Challenges Research Fund
- European Research Council (ERC) [726318] Funding Source: European Research Council (ERC)
Both animal models and human studies have demonstrated the significant role of immune and inflammatory mechanisms in hypertension and its related complications. Immune-modulating interventions, including non-specific approaches and targeted medications, have shown promise in lowering blood pressure, reducing organ damage, and managing cardiovascular risk in both experimental and small clinical studies. Further targeted studies are needed to evaluate their effects in hypertensive individuals.
Both animal models and human observational and genetic studies have shown that immune and inflammatory mechanisms play a key role in hypertension and its complications. We review the effects of immunomodulatory interventions on blood pressure, target organ damage, and cardiovascular risk in humans. In experimental and small clinical studies, both non-specific immunomodulatory approaches, such as mycophenolate mofetil and methotrexate, and medications targeting T and B lymphocytes, such as tacrolimus, cyclosporine, everolimus, and rituximab, lower blood pressure and reduce organ damage. Mechanistically targeted immune interventions include isolevuglandin scavengers to prevent neo-antigen formation, co-stimulation blockade (abatacept, belatacept), and anti-cytokine therapies (e.g. secukinumab, tocilizumab, canakinumab, TNF-alpha inhibitors). In many studies, trial designs have been complicated by a lack of blood pressure-related endpoints, inclusion of largely normotensive study populations, polypharmacy, and established comorbidities. Among a wide range of interventions reviewed, TNF-alpha inhibitors have provided the most robust evidence of blood pressure lowering. Treatment of periodontitis also appears to deliver non-pharmacological anti-hypertensive effects. Evidence of immunomodulatory drugs influencing hypertension-mediated organ damage are also discussed. The reviewed animal models, observational studies, and trial data in humans, support the therapeutic potential of immune-targeted therapies in blood pressure lowering and in hypertension-mediated organ damage. Targeted studies are now needed to address their effects on blood pressure in hypertensive individuals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据